NASDAQ · RPID
Healthcare · Medical - Devices
$0.90
Down-$0.04 (-4.76%)
Updated Oct 8, 2026, 5:44 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RPID
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
RPID closed at $0.90 after 21 trading sessions, down 25.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $0.9722 | $0.9944 | $0.891 | $0.8977 | 218.86K |
| Oct 6, 2026 | $1.00 | $1.00 | $0.9426 | $0.9426 | 162.26K |
| Oct 5, 2026 | $0.9122 | $1.15 | $0.9122 | $0.9764 | 444.78K |
| Oct 2, 2026 | $0.96 | $0.9999 | $0.8604 | $0.92 | 329.28K |
| Oct 1, 2026 | $1.06 | $1.06 | $0.919 | $0.921 | 525.66K |
| Sep 30, 2026 | $1.10 | $1.10 | $1.03 | $1.03 | 179.9K |
| Sep 29, 2026 | $1.18 | $1.1801 | $1.065 | $1.08 | 334.27K |
| Sep 28, 2026 | $1.13 | $1.1799 | $1.08 | $1.095 | 268.31K |
| Sep 25, 2026 | $1.13 | $1.145 | $1.11 | $1.11 | 171.62K |
| Sep 24, 2026 | $1.10 | $1.12 | $1.095 | $1.11 | 504.37K |
| Sep 23, 2026 | $1.18 | $1.1896 | $1.095 | $1.11 | 173.82K |
| Sep 22, 2026 | $1.14 | $1.19 | $1.135 | $1.14 | 641.03K |
| Sep 21, 2026 | $1.15 | $1.15 | $1.13 | $1.13 | 260.15K |
| Sep 18, 2026 | $1.11 | $1.20 | $1.09 | $1.12 | 721.1K |
| Sep 17, 2026 | $1.13 | $1.15 | $1.09 | $1.09 | 690.38K |
| Sep 16, 2026 | $1.16 | $1.18 | $1.11 | $1.11 | 265K |
| Sep 15, 2026 | $1.19 | $1.19 | $1.13 | $1.15 | 213.11K |
| Sep 14, 2026 | $1.23 | $1.23 | $1.155 | $1.17 | 172.36K |
| Sep 11, 2026 | $1.22 | $1.26 | $1.20 | $1.23 | 205.7K |
| Sep 10, 2026 | $1.20 | $1.2372 | $1.16 | $1.20 | 385.17K |
| Sep 9, 2026 | $1.24 | $1.255 | $1.18 | $1.21 | 409.34K |
The latest Smart Investors Daily articles mentioning RPID.
Company
Market Activity
Research & News
RPID research
Company profile and research snapshot.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Roth Capital | Buy | — |
| May 29, 2026 | Keybanc | Overweight | — |
| May 22, 2026 | Lake Street | Buy | — |
| Jul 28, 2025 | Lake Street | Buy | — |
| Feb 12, 2025 | Keybanc | Overweight | — |
No generated briefing is available yet.
Benzinga · Sep 29, 2026
Roth Capital analyst Max Masucci initiates coverage on Rapid Micro Biosystems (NASDAQ:RPID) with a Buy rating and announces Price Target of $3.
SeekingAlpha · Sep 24, 2026
2026-09-24. The following slide deck was published by Rapid Micro Biosystems, Inc.
Yahoo · Sep 4, 2026
LEXINGTON, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced plans to participate in the following upcoming investor conferences: Thursday, September 10, 2026 - Lake Street’s 10th Annual Best Ideas Growth (BIG) Conference in New York, NY. The Comp
Yahoo · Sep 4, 2026
Rapid Micro Biosystems (RPID) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RPID.
